Drug delivery

Orthopaedic surgery
#Drug delivery #Funding #Gene therapy #Innovate UK #TherageniX #University of Nottingham

Innovate UK grant for powdered gene therapy

TherageniX and the University of Nottingham have been awarded a £995,000 ($1,252,585) grant from Innovate UK, the UK’s innovation agency. The funding will support the development of the company’s gene therapy in a powder, a non-viral gene delivery system to improve tissue regeneration following surgery. Read More

#News

Gastrointestinal tract
#Drug delivery #Gastrointestinal #Precision medicine #Triastek

3D-printed oral treatment for ulcerative colitis proves successful

A first in human study of a 3D printing drug product, T21, designed to treat moderate to severe ulcerative colitis (UC), has reported positive results. Imaging results from the study confirmed that T21 tablets are precisely delivered and released to the target site (the colon) for… Read More

#News

Subcutaneous injection
#Antibody #Autoimmune disease #Drug delivery #FDA #Halozyme #Phase III trial

FDA approves subcutaneous injectable for myasthenia gravis

The US Food and Drug Administration (FDA) has given approval to Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with Enhanze for subcutaneous (SC) use for the treatment of generalised myasthenia gravis (gMG). The treatment is approved in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Read More

#News #Regulatory

#Aptamer Group #Aptamers #Automation #Drug delivery #Gene delivery #Gene therapy #Molecular Biology #Oncology #Precision medicine #Turning Science into Business

Turning science into business: An optimised alternative to antibodies

From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley. DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did… Read More

#Exclusive Content

Leukaemia
#Acute Myeloid Leukaemia #Cancer research #Drug delivery

Potential treatment for patients with acute myeloid leukaemia 

Ellipses Pharma, a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, has been granted Orphan Drug Designation (ODD) by the FDA for EP0042, a dual FLT-3 and Aurora kinase inhibitor, for the treatment of acute myeloid leukaemia… Read More

#Cancer Research #News

Researcher pipetting samples in microplate
#Drug delivery #Funding #Genetics #Genetics / genomics #Investment #Start-ups

Start-up aims to advance transformative genetic medicines

Aera Therapeutics has launched with a vision to “unlock the potential of genetic medicines across a wide range of modalities and therapeutic areas”.   The company’s delivery platform is based on research conducted in the laboratory of scientific founder Feng Zhang and aims to address the limitations of… Read More

#News #Start-up Zone

#AAV #Cell and gene therapy #Drug delivery #Gene delivery #Gene therapy #mRNA #Nanomedicine / nanotechnology #Ophthalmology

Lipid nanoparticles and mRNA used to treat hereditary blindness

Oregon State University College of Pharmacy scientists have shown that lipid nanoparticles and messenger RNA could treat blindness associated with a rare genetic condition.  Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible. … Read More

#News #Trending News

Year change from 2022 to 2023
#Clinical trial #Clinical trial design #Covid-19 #Drug delivery #Drug development #Healthcare

Drug discovery predictions: Analysis and insight 

In January 2022, DDW’s Megan Thomas spoke to decision-makers from the drug discovery industry about their predictions on what 2022 holds for our sector. As we head into 2023, DDW will be publishing a series of reflections on these predictions. Here, Thomas reflects specifically… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Cell and gene therapy #Collaboration #Drug delivery #Drug discovery

Partnership hopes to improve large-scale exosome production

Bio-chromatography company Sartorius BIA Separations (BIA) and exosomes medicines company Exopharm have signed a Material Transfer Agreement and associated collaborative programme.  The partnership aims to combine Exopharm’s LEAP technology together with BIA’s CIM (Convective Interaction Media) monolith chromatography for improved large-scale therapeutic exosome production and commercialisation. … Read More

#Business & Investment #News

Lipid nanoparticle mRNA vaccine
#CPHI Excellence in Pharma Award #Drug delivery #mRNA #Polymer-based drug delivery

Polymer-based drug delivery system for mRNA wins award

A new polymer-based drug delivery system for mRNA and other nucleic acids has won the CPHI Excellence in Pharma Award in the category “Packaging and Drug Delivery”.  The system was developed by Evonik Health Care together with researchers at Stanford University.  Developed together with Professors… Read More

#News

#Drug delivery #Drug development #Drug discovery #Mucoadhesive drug delivery

Unlocking the potential of mucoadhesive drug delivery

Listen to this article on the DDW Podcast: Ashley Rein, Global Market Manager for Topical Drug Delivery at Lubrizol Life Science Health (LLS Health), explains how by using mucoadhesive drug delivery, developers can bring novel drugs to market and maximise the efficacy of pre-existing APIs. … Read More

#Exclusive Content

#Drug delivery #Drug development #Formulation

Streamlining development with containment in early drug discovery

Gurmeet Singh, Senior Director at West Pharmaceutical Services & Jeff Kyle, Senior Director of Wearable Delivery Systems explore how a focus on containment in early drug discovery can help ease the development process later on. It may seem counterintuitive to spend time and money on planning for containment… Read More

#Exclusive Content

Lungs
#Asthma #COPD #Drug delivery #Transpire Bio

Transpire Bio & Recipharm to develop inhaled medicines 

Pharmaceutical company Transpire Bio will work alongside drug delivery provider Recipharm to develop two inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).   Transpire Bio announced a definitive agreement with Recipharm to develop its TRB-1 and TRB-2 inhaled medicines. These are… Read More

#News

#Biotechnology #Drug delivery #Immunotherapy

Calidi granted US patent for immunotherapy platform

Biotechnology company Calidi Biotherapeutics has been granted a US patent for its SuperNova (SNV) technology platform. Calidi’s SNV platform is composed of allogeneic, adipose-derived mesenchymal stem cells (AD-MSC) loaded with an oncolytic agent. The company aims to use it in combination with various immunotherapy agents, including blocking antibodies. The SNV platform is designed to shield oncolytic viral payloads from the… Read More

#News

#Clinical trials #Drug delivery

ISA Pharmaceuticals cancer trial using drug delivery technology  

Biotech ISA Pharmaceuticals has launched a clinical trial using its Amplivant adjuvant technology which will enable the delivery of a cancer vaccine in patients.  The clinical trial, run by partner Scancell Holdings, is a multicentre clinical trial testing Scancell’s Modi-1 vaccine in patients with triple negative… Read More

#News

#Antibodies #Drug delivery

New range of detection reagents for R&D and diagnostic markets 

Jackson ImmunoResearch, manufacturers of secondary antibodies and immunoreagents for the life science market, has announced a new range of detection reagents for improved image quality.  Nano Secondaries   Jackson ImmunoResearch Nano Secondaries are polyclonal VHH Fragment antibodies (Nanobodies*) produced in Alpacas. They are available with specificity… Read More

#News